الفهرس Only 14 pages are availabe for public view
 |  | from | 70 |  |  |
| | | from | 70 | | |
Abstract
SAARD monotherapy is rarly ‘ remission inducing’ thus many if not most, patient with RA are candidates for combination therapy
In this study two SAARD combinations were selected MTX/SSZ and MTX/HCQ. Both combination represented two rationales for SAARD combination; one this drugs having same mode of action, thus giving increased efficay by synergism, or at leaset additive effect while the order with drugs of different modes of action and different toxicities thus giving higher efficacy/ toxicity ratio.
This researsh aimed at studing the effect of these combinations on ESR, CRP, SSA and AKA in addition to other clinical and laboratory variables to achive this goal we carried out to prospective 12 weeks follow up study of 30 AKA-positive RA female patients who recevied either combinations.